23,000 Shares in GRAIL, Inc. $GRAL Purchased by Banque Transatlantique SA

Banque Transatlantique SA acquired a new stake in shares of GRAIL, Inc. (NASDAQ:GRAL) in the fourth quarter, according to the company in its most recent filing with the SEC. The firm acquired 23,000 shares of the company’s stock, valued at approximately $1,969,000.

Other large investors also recently added to or reduced their stakes in the company. Farallon Capital Management LLC boosted its holdings in shares of GRAIL by 73.7% in the fourth quarter. Farallon Capital Management LLC now owns 2,342,684 shares of the company’s stock valued at $200,510,000 after purchasing an additional 993,684 shares during the period. Baker BROS. Advisors LP grew its position in shares of GRAIL by 27.9% during the 4th quarter. Baker BROS. Advisors LP now owns 2,085,333 shares of the company’s stock worth $178,484,000 after buying an additional 455,208 shares in the last quarter. Vanguard Group Inc. grew its position in shares of GRAIL by 9.0% during the 4th quarter. Vanguard Group Inc. now owns 1,980,783 shares of the company’s stock worth $169,535,000 after buying an additional 163,790 shares in the last quarter. State Street Corp increased its stake in shares of GRAIL by 38.8% during the fourth quarter. State Street Corp now owns 1,827,523 shares of the company’s stock valued at $156,418,000 after buying an additional 510,546 shares during the period. Finally, Morgan Stanley increased its stake in shares of GRAIL by 63.8% during the fourth quarter. Morgan Stanley now owns 1,511,687 shares of the company’s stock valued at $129,385,000 after buying an additional 588,647 shares during the period.

GRAIL Stock Performance

GRAL stock opened at $63.74 on Friday. GRAIL, Inc. has a one year low of $29.95 and a one year high of $118.84. The firm has a market cap of $2.74 billion, a price-to-earnings ratio of -6.15 and a beta of 3.15. The firm has a 50-day simple moving average of $58.84 and a two-hundred day simple moving average of $72.91.

GRAIL (NASDAQ:GRAL) last issued its quarterly earnings data on Tuesday, May 5th. The company reported ($2.29) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($2.76) by $0.47. The firm had revenue of $40.78 million for the quarter, compared to the consensus estimate of $39.16 million. GRAIL had a negative net margin of 253.22% and a negative return on equity of 16.42%. As a group, equities analysts predict that GRAIL, Inc. will post -10.99 earnings per share for the current fiscal year.

Insider Activity

In other GRAIL news, CEO Robert P. Ragusa sold 123,502 shares of GRAIL stock in a transaction on Wednesday, April 8th. The shares were sold at an average price of $49.92, for a total value of $6,165,219.84. Following the transaction, the chief executive officer directly owned 518,582 shares of the company’s stock, valued at approximately $25,887,613.44. The trade was a 19.23% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Andrew John Partridge sold 1,491 shares of the company’s stock in a transaction on Thursday, June 4th. The stock was sold at an average price of $61.08, for a total value of $91,070.28. Following the transaction, the insider directly owned 163,738 shares in the company, valued at approximately $10,001,117.04. The trade was a 0.90% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 232,464 shares of company stock valued at $11,621,242 in the last ninety days. 1.83% of the stock is currently owned by insiders.

Analysts Set New Price Targets

A number of analysts recently weighed in on GRAL shares. Robert W. Baird set a $70.00 price objective on shares of GRAIL in a research note on Wednesday, May 6th. Morgan Stanley cut their target price on shares of GRAIL from $110.00 to $60.00 and set an “equal weight” rating on the stock in a research report on Tuesday, February 24th. Mizuho began coverage on shares of GRAIL in a report on Friday, April 10th. They issued a “neutral” rating and a $58.00 price target for the company. The Goldman Sachs Group assumed coverage on shares of GRAIL in a research report on Friday, June 5th. They issued a “neutral” rating and a $60.00 price target for the company. Finally, Wall Street Zen upgraded shares of GRAIL from a “sell” rating to a “hold” rating in a research note on Saturday, May 9th. Four research analysts have rated the stock with a Buy rating, five have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $67.00.

GRAIL Profile

GRAIL, Inc (NASDAQ: GRAL) is a biotechnology company dedicated to the early detection of cancer through a multi-cancer blood test. Leveraging advances in next-generation sequencing, cell-free DNA (cfDNA) analysis and machine learning, GRAIL has developed the Galleri™ test, which aims to identify more than 50 types of cancer at their earliest stages. The company’s platform analyzes methylation patterns in circulating tumor DNA to pinpoint tumor presence and tissue of origin, enabling physicians to pursue timely diagnostic follow-up.

Founded in 2016 as a spin-out from Illumina, GRAIL established its headquarters in Menlo Park, California, with additional research and operations centers in the United Kingdom.